FDA Clearance Tracker · P230009-S010
Shield
Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jul 22, 2026
Approved
Time to decision
250 days
Received Nov 14, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P230009-S010
- Device name
- Shield
- Applicant
- Guardant Health, Inc.
- Applicant location
- Palo Alto, CA
- Received
- Nov 14, 2025
- Decided
- Jul 22, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P230009
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for a change to the Shield EP1 classification model which streamlines Guardant Shield to a methylation-only workflow, removing fragmentomic and somatic components.
Source documents
Other decisions for Guardant Health, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P250027 · Decided May 19, 2026 · 292 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.